R to @EMA_News: A third of all new medicines with a positive opinion in 2023 targeted cancer , i.e. 2⃣5⃣ new cancer medicines were recommended for approval last year.
🐦🔗: https://nitter.cz/EMA_News/status/1747253496460784019#m
[2024-01-16 13:44 UTC]
#EMAPresser
R to @EMA_News: We published an overview of human medicines highlights this morning ⬇️
https://x.com/EMA_News/status/1747204037701669370?s=20
🐦🔗: https://nitter.cz/EMA_News/status/1747250732598751700#m
[2024-01-16 13:33 UTC]
R to @EMA_News: Watch live 🔴
We are now starting our press briefing on medicines that were approved last year and trends we are observing in human medicines.
Don’t miss our tweets 🧵 during the press briefing. Follow #EMAPresser
🐦🔗: https://nitter.cz/EMA_News/status/1747250220000289243#m
[2024-01-16 13:31 UTC]
R to @EMA_News: Therapeutic areas with the highest numbers of new approval recommendations:
1⃣ oncology,
2⃣ neurology,
3⃣ cardiovascular.
🐦🔗: https://nitter.cz/EMA_News/status/1747251070345077176#m
[2024-01-16 13:34 UTC]
R to @EMA_News: Half of our positive recommendations on new therapeutic indications for existing medicines were for treatment of children 👦👧
This figure is considerably higher than in previous years.
#EMAPresser #MedicinesForChildren
🐦🔗: https://nitter.cz/EMA_News/status/1747252124348723345#m
[2024-01-16 13:39 UTC]
R to @EMA_News: We provided 2 recommendations for use of medicines outside the 🇪🇺 (#EUM4All):
🔶 a new treatment option for 50 million children with a tropical disease caused by parasites
🔶a medicine to treat an acute and lethal form of sleeping sickness
@WHO #EMAPresser #GlobalHealth
🐦🔗: https://nitter.cz/EMA_News/status/1747252409414602791#m
[2024-01-16 13:40 UTC]
R to @EMA_News: Last year, we also continued our work to tackle #COVID19, in particular with the evaluation of a new vaccine and 3 updated vaccines. 💉
🐦🔗: https://nitter.cz/EMA_News/status/1747253014438838691#m
[2024-01-16 13:42 UTC]
R to @EMA_News: We are committed to progressing treatments against #cancer and to supporting Europe’s beating cancer plan.
Cancer is an area of high unmet medical need and a major health concern in the 🇪🇺.
#EMAPresser #EUCancerPlan #HealthUnion
🐦🔗: https://nitter.cz/EMA_News/status/1747253264356405351#m
[2024-01-16 13:43 UTC]
R to @EMA_News: To support development and earlier assessment of medicines that address unmet medical needs for #cancer patients
➡️ 7 were reviewed in view of a conditional marketing authorisation
➡️ 1 had accelerated assessment
➡️ 2 were part of the #PRIME scheme
🐦🔗: https://nitter.cz/EMA_News/status/1747253499493261624#m
[2024-01-16 13:44 UTC]
R to @EMA_News: #Cancer is an area where top innovation and scientific progress happen quickly. That’s why EMA decided to use this therapeutic area as a pathfinder to improve medicines evaluation overall. #EMAPresser
🐦🔗: https://nitter.cz/EMA_News/status/1747253899109822673#m
[2024-01-16 13:46 UTC]
EMA and the EU network will keep monitoring the #safety of #COVID19vaccines and therapeutics, as we do for all authorised medicines in the 🇪🇺. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080323002839046
The available data confirm that the #COVID19vaccines are safe and add to the evidence from the clinical trials.
Most of the side effects of the vaccines are mild and short-lived. Serious side effects are very rare.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080218505940996
If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.
The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080058241581057
We have encouraged people who received the #Covid19vaccine and healthcare professionals to report suspected side effects.
Out of nearly 1 billion vaccines administered, Eudravigilance received more than 1.7 million reports in the EU.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079807732580361
To ensure #transparency regarding the results of the assessment of the monthly #safetyreports of #Covid19vaccines and keep the public informed, we published 5⃣0⃣ monthly safety updates providing an up-to-date overview of the safety profile of the vaccines. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079623208370182
We placed extra obligations on the #Covid19vaccine makers.
They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079498784366597
To fight the pandemic the #Covid19vaccineshad to be rolled out quickly across the 🇪🇺.
So we made sure that we put in place enhanced #safetymonitoring and a comprehensive plan which guided us in analysing the data from vaccination campaigns.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079359399235592
EMA's Emergency Task Force discussed 3⃣0⃣0⃣ therapeutics and 7⃣0⃣ vaccines in more than 2⃣5⃣0⃣ meetings held during the #publichealth emergency.
It continues its work to be prepared for any new emerging health threats.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079159830073353
EMA will continue to work on therapeutics. 💊
We will monitor any new antivirals that are easier to administer, and any monoclonal antibodies targeting new variants, which could improve the protection of the vulnerable against #COVID19.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666078996596129797
EMA-@ECDC_EU recommendation: A monovalent #vaccine including an XBB strain is recommended for the update of vaccines to be used in the autumn vaccination campaigns.
Updated vaccines could be used for revaccination, but also for primary vaccination.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666078341395542017
Client Info
Server: https://mastodon.social
Version: 2025.04
Repository: https://github.com/cyevgeniy/lmst